Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Year: 2013
Type: review
Abstract: Nearly 350 IgG-based therapeutics are approved for clinical use or are under development for many diseases lacking adequate treatment options. These include molecularly engineered biologicals comprising the IgG Fc-domain fused to various effector molecules (so-called Fc-fusion proteins) that confer the advantages of IgG, including binding to the neonatal Fc receptor (FcRn) to facilitate in vivo stability, and the therapeutic benefit of the specific effector functions. Advances in IgG structure-function relationships and an understanding of FcRn biology have provided therapeutic opportunities for previously unapproachable diseases. This article discusses approved Fc-fusion therapeutics, novel Fc-fusion proteins and FcRn-dependent delivery approaches in development, and how engineering of the FcRn-Fc interaction can generate longer-lasting and more effective therapeutics.
Authors: Timo Rath, Kristi Baker, Jennifer A. Dumont, Robert T. Peters, Haiyan Jiang, Shuo-Wang Qiao, Wayne I. Lencer, Glenn F. Pierce, Richard S. Blumberg
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Awards: Mechanism of action for the epithelial-specific ER stress sensor IRE1β in regulating intestinal homeostasis and host defense, FcRn-dependent sorting of IgG and IgG-opsinized antigens by epithelial cells, G3744223265, G397724349, G4335173828, Intestinal Disease-enterocyte toxin interaction, Intestinal Immune Regulation by IgG and FcRn, Intestinal Immune Regulation by IgG and FcRn, Unsaturated glycoceramide as novel platform for mucosal vaccine and drug delivery, Characterization of Mucosal Lymphocytes, Regulation of Mucosal Lymphocytes, Integrated Epithelial and Muscosal Biology, Characterization of Mucosal Lymphocytes, Endoplasmic reticulum stress and intestinal inflammation
OpenAlex ID: W2094058129